Mellin, G.W. & Katzenstein, M. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N. Engl. J. Med. 267, 1238–1244 (1962).
Shortt, J., Hsu, A.K. & Johnstone, R.W. Thalidomide-analog biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 32, 4191–4202 (2013).
Bartlett, J.B., Dredge, K. & Dalgleish, A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4, 314–322 (2004).
Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345–1350 (2010).
Zhu, Y.X. et al. Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood 118, 4771–4779 (2011).
Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326–2335 (2012).
Lee, J. & Zhou, P. DCAFs, the missing link of the CUL4–DDB1 ubiquitin ligase. Mol. Cell 26, 775–780 (2007).
Angers, S. et al. Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery. Nature 443, 590–593 (2006).
Fischer, E.S. et al. Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49–53 (2014).
Chamberlain, P.P. et al. Structure of the human cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803–809 (2014).
Jo, S., Lee, K.H., Song, S., Jung, Y.K. & Park, C.S. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channels in rat brain. J. Neurochem. 94, 1212–1224 (2005).
Lee, K.M., Jo, S., Kim, H., Lee, J. & Park, C.S. Functional modulation of AMP-activated protein kinase by cereblon. Biochim. Biophys. Acta 1813, 448–455 (2011).
Iacono, K.T., Brown, A.L., Greene, M.I. & Saouaf, S.J. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp. Mol. Pathol. 83, 283–295 (2007).
Kirk, P. et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4, and facilitates their cell surface expression. EMBO J. 19, 3896–3904 (2000).
Parks, S.K., Chiche, J. & Pouysségur, J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 13, 611–623 (2013).
Walters, D.K., Arendt, B.K. & Jelinek, D.F. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle 12, 3175–3183 (2013).
Arendt, B.K. et al. Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia 26, 2286–2296 (2012).
Zhu, D. et al. The cyclophilin A–CD147 complex promotes the proliferation and homing of multiple-myeloma cells. Nat. Med. 21, 572–580 (2015).
Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple-myeloma cells. Science 343, 301–305 (2014).
Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305–309 (2014).
Gandhi, A.K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN. Br. J. Haematol. 164, 811–821 (2014).
Zhu, Y.X. et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 124, 536–545 (2014).
Krönke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1-α in del(5q) MDS. Nature 523, 183–188 (2015).
Petzold, G., Fischer, E.S. & Thomä, N.H. Structural basis of lenalidomide-induced CK1-α degradation by the CRL4CRBN ubiquitin ligase. Nature 532, 127–130 (2016).
Chesi, M. et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376–385 (2012).
Smith, C.K., Baker, T.A. & Sauer, R.T. Lon and Clp family proteases and chaperones share homologous substrate-recognition domains. Proc. Natl. Acad. Sci. USA 96, 6678–6682 (1999).
Gandhi, A.K. et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br. J. Haematol. 164, 233–244 (2014).
Tang, Y. et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 65, 3193–3199 (2005).
Strupp, C., Hildebrandt, B., Germing, U., Haas, R. & Gattermann, N. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia 17, 1200–1202 (2003).
Kelaidi, C. et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk. Res. 32, 1049–1053 (2008).
Fenaux, P. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC-transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118, 3765–3776 (2011).
List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456–1465 (2006).
Giagounidis, A. et al. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann. Hematol. 93, 1–11 (2014).
Mahony, C. et al. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and non-neurotoxic in vitro. Proc. Natl. Acad. Sci. USA 110, 12703–12708 (2013).
Bassermann, F., Eichner, R. & Pagano, M. The ubiquitin–proteasome system—implications for cell cycle control and the targeted treatment of cancer. Biochim. Biophys. Acta 1843, 150–162 (2014).
Kumar, S.K. et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 15, 1503–1512 (2014).
Roussel, M. et al. Front-line transplantation program with lenalidomide, bortezomib and dexamethasone combination as induction and consolidation, followed by lenalidomide maintenance in patients with multiple myeloma: a phase 2 study by the Intergroupe Francophone du Myélome. J. Clin. Oncol. 32, 2712–2717 (2014).
Richardson, P.G. et al. Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679–686 (2010).
Stewart, A.K. et al. Carfilzomib, lenalidomide and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372, 142–152 (2015).
Harrison, J.S., Rameshwar, P., Chang, V. & Bandari, P. Oxygen saturation in the bone marrow of healthy volunteers. Blood 99, 394 (2002).
Staffler, G. et al. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J. Immunol. 171, 1707–1714 (2003).
Hu, J. et al. Involvement of HAb18G–CD147 in T cell activation and immunological synapse formation. J. Cell. Mol. Med. 14, 2132–2143 (2010).
Landskron, J. & Taskén, K. CD147 in regulatory T cells. Cell. Immunol. 282, 17–20 (2013).
Tehranchi, R. et al. Granulocyte-colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101, 1080–1086 (2003).
Gloeckner, C.J., Boldt, K., Schumacher, A., Roepman, R. & Ueffing, M. A novel tandem-affinity purification strategy for the efficient isolation and characterization of native protein complexes. Proteomics 7, 4228–4234 (2007).
Le Floch, R. et al. CD147 subunit of lactate–H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. USA 108, 16663–16668 (2011).
Birsoy, K. et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet. 45, 104–108 (2013).
Lo, Y.H., Ho, P.C. & Wang, S.C. Epidermal growth factor receptor protects proliferating cell nuclear antigen from cullin 4A protein-mediated proteolysis. J. Biol. Chem. 287, 27148–27157 (2012).
Bassermann, F. et al. The Cdc14B–Cdh1–Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 134, 256–267 (2008).
Fernández-Sáiz, V. et al. SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nat. Cell Biol. 15, 72–81 (2013).
Baumann, U. et al. Disruption of the PRKCD–FBXO25–HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nat. Med. 20, 1401–1409 (2014).
Schmid, B. et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction and reduced motor neuron axon outgrowth. Proc. Natl. Acad. Sci. USA 110, 4986–4991 (2013).
Kennedy, B.N. et al. Zebrafish rx3 and mab21l2 are required during eye morphogenesis. Dev. Biol. 270, 336–349 (2004).